Get the Stockscreener App
2.11
2.76%
-0.06
After Hours:
2.10
-0.010
-0.47%
Heron Therapeutics Inc stock is traded at $2.11, with a volume of 1.71M.
It is down -2.76% in the last 24 hours and up +12.23% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$2.17
Open:
$2.17
24h Volume:
1.71M
Relative Volume:
0.94
Market Cap:
$352.35M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-13.19
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
-8.66%
1M Performance:
+12.23%
6M Performance:
+20.57%
1Y Performance:
-28.23%
1-Day Range:
$2.10
$2.255
1-Week Range:
$2.0001
$2.61
52-Week Range:
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
2.11 | 352.35M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Results: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates - simplywall.st
Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Traders Buy Large Volume of Call Options on Heron Therapeutics (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (NASDAQ:HRTX) - Seeking Alpha
Heron settles patent dispute with Viatris over antiemetic agents - MSN
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Heron Therapeutics Reports Strong Q1 2025 Results - TipRanks
Heron Therapeutics Q1 2025 Earnings: Strong Growth Amid Challenges - TipRanks
Heron Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Heron Therapeutics (HRTX) Resolves Patent Dispute with Viatris - GuruFocus
Heron Settles Patent Litigation With Mylan Over Cinvanti, Aponvie; Shares Rise - marketscreener.com
Heron stock up as Viatris patent dispute ends (HRTX:NASDAQ) - Seeking Alpha
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surges - Investing.com Canada
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
HRTX Achieves Record Q1 Revenue, Surpassing Expectations | HRTX Stock News - GuruFocus
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates - The Malaysian Reserve
Heron Therapeutics (HRTX) Settles Patent Disputes with Mylan Pharmaceuticals | HRTX Stock News - GuruFocus
Heron Therapeutics Q1 2025 Financial Results - TradingView
Heron Therapeutics: Q1 Earnings Snapshot - marketscreener.com
HERON THERAPEUTICS, INC. /DE/ SEC 10-Q Report - TradingView
Heron Therapeutics settles patent litigation with Mylan By Investing.com - Investing.com India
Heron Therapeutics Announces Settlement With Mylan Related To Cinvanti® And Aponvie® Patent Litigations - marketscreener.com
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations - PR Newswire
Invesco Ltd. Grows Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics settles patent litigation with Mylan - Investing.com
Heron Therapeutics (HRTX) Awaits Q1 Earnings Report - GuruFocus
Marshall Wace LLP Cuts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Projected to Post Earnings on Tuesday - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Adage Capital Partners GP L.L.C. Decreases Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Renaissance Technologies LLC Has $1.82 Million Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by LPL Financial LLC - Defense World
Healthy Upside Potential: Heron Therapeutics Inc (HRTX) - Sete News
American Society of Anesthesiologists Announces Heron Therapeutics as Industry Supporter for Seventh Year | Newswise - Newswise
HRTX stock rated a Buy by Rodman & Renshaw - knoxdaily.com
It would be worthwhile to take a closer look at Heron Therapeutics Inc (HRTX) - uspostnews.com
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Heron Therapeutics Appoints Mark Hensley as COO - TipRanks
Heron Therapeutics Names Mark Hensley as COO - marketscreener.com
Heron Therapeutics Strengthens Leadership: Former Veloxis CEO Takes COO Role with Major Stock Package - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Heron Therapeutics (NASDAQ:HRTX) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Geode Capital Management LLC Sells 30,034 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Investor’s Delight: Heron Therapeutics Inc (HRTX) Closes Strong at 1.88, Up 6.21 - DWinneX
Financial Metrics Exploration: Understanding Heron Therapeutics Inc (HRTX) Through Ratios - DWinneX
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):